Rein Therapeutics (RNTX) Assets (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Assets of $26.3 million for Q1 2026, down 54.38% year-over-year from $57.6 million in Q1 2025, and up 8.82% quarter-over-quarter from $24.2 million in Q4 2025.
Rein Therapeutics (RNTX) Assets (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Assets for 11 consecutive years, with $26.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 54.38% year-over-year to $26.3 million; the TTM figure through Mar 2026 stood at $26.3 million (down 54.38% YoY), while the FY2025 annual figure was $24.2 million, down 61.15% from the prior year.
- Assets advanced to $26.3 million in Q1 2026 per RNTX's latest filing, from $24.2 million in the prior quarter.
- Across five years, Assets topped out at $109.4 million in Q2 2024 and bottomed at $12.8 million in Q3 2023.
- Historically, Assets has averaged $51.0 million across 5 years, with a median of $40.3 million in 2022.
- Annual changes were most pronounced in 2024 — Assets surged 712.8% — and 2025, when it slumped 61.15%.
- Rein Therapeutics' Assets stood at $22.0 million in 2022, then soared by 381.7% to $106.0 million in 2023, then sank by 41.33% to $62.2 million in 2024, then plunged by 61.15% to $24.2 million in 2025, then increased by 8.82% to $26.3 million in 2026.
- Business Quant data shows RNTX's Assets at $26.3 million in Q1 2026, $24.2 million in Q4 2025, and $53.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | 65.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.97 Mn |
| Mar 31, 2026 | 26.29 Mn |
| Dec 31, 2025 | 24.16 Mn |
| Sep 30, 2025 | 53.71 Mn |
| Jun 30, 2025 | 57.48 Mn |
| Mar 31, 2025 | 57.63 Mn |
| Dec 31, 2024 | 62.19 Mn |
| Sep 30, 2024 | 104.22 Mn |
| Jun 30, 2024 | 109.40 Mn |
| Mar 31, 2024 | 99.19 Mn |
| Dec 31, 2023 | 106.01 Mn |
| Sep 30, 2023 | 12.82 Mn |
| Jun 30, 2023 | 13.99 Mn |
| Mar 31, 2023 | 17.16 Mn |
| Dec 31, 2022 | 22.01 Mn |
| Sep 30, 2022 | 27.23 Mn |
| Jun 30, 2022 | 33.77 Mn |
| Mar 31, 2022 | 40.26 Mn |
| Dec 31, 2021 | 48.48 Mn |
| Sep 30, 2021 | 54.77 Mn |